Beijing, China, August,11, 2026
Datasea Intelligent Technology Ltd. has announced that its variable interest entity, Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd., has completed U.S. Food and Drug Administration establishment registration and device listing for the NeuroVibe Biofeedback System, including the NV-02 and NV-03 products. The devices are listed under FDA product code HCC as Class II 510(k)-exempt biofeedback medical devices within the Neurology regulatory area. The milestone supports Datasea’s strategy to advance its acoustic artificial intelligence, non-invasive brain-computer interface and biofeedback technologies toward regulated commercial applications. Importantly, FDA establishment registration and device listing do not constitute FDA approval, clearance or authorization of either the establishment or the listed devices.
NeuroVibe Combines Acoustic AI and Biofeedback Technology
The NeuroVibe Biofeedback System is designed as a non-invasive platform combining acoustic stimulation, transcranial vibro-acoustic stimulation, electroencephalogram (EEG) signal acquisition and AI-assisted health management. According to Datasea, the integrated architecture is intended to collect and analyze physiological signals in real time and provide biofeedback that can support neurological function assessment, training, brain health management and related applications. Acoustic stimulation uses selected frequencies as physical inputs intended to modulate neural states, while transcranial vibro-acoustic stimulation provides a non-invasive neuromodulation component.
EEG acquisition is designed to capture brainwave signals, and the system’s AI-assisted analysis processes individual data to support feedback optimization. Together, these technologies create a closed-loop approach combining physical stimulation, physiological signal monitoring, intelligent analysis and biofeedback.Datasea views this architecture as a way to differentiate NeuroVibe from conventional EEG acquisition systems. Rather than functioning solely as hardware for recording brain signals, NeuroVibe is intended to integrate acoustic input, neural signal acquisition, AI-driven analysis and feedback mechanisms into a broader technology platform.
FDA Listing Supports U.S. Commercialization Strategy
Advertisement
Completion of the FDA establishment registration and device listing represents a regulatory milestone as Datasea works to transition NeuroVibe from research and development toward potential commercial deployment. The NV-02 and NV-03 products are listed as Class II 510(k)-exempt biofeedback devices, meaning the devices fall within a classification that is exempt from premarket notification requirements, subject to applicable regulatory requirements and limitations. Datasea emphasized that this status should not be confused with FDA approval or FDA 510(k) clearance. Establishment registration and device listing are regulatory requirements and do not represent an FDA determination that the devices have been approved, cleared or authorized.
The company expects early U.S. commercialization efforts to focus on applications aligned with the devices’ listed classification and intended use. Potential areas identified by Datasea include brain health management, neurological function assessment, biofeedback training, stress relaxation, sleep improvement and cognitive maintenance. Future commercialization will depend on continued regulatory compliance, product development, application validation and market adoption.
Datasea Advances Non-Invasive Neurotechnology Platform
Datasea has previously announced two acoustic-driven brain-computer interface (BCI) systems supporting its broader medical technology strategy. One system is designed to enhance EEG signal quality using acoustic physical fields, while another focuses on creating a real-time closed loop between vibration stimulation and neural feedback. The company believes these technologies could support individualized feature extraction, feedback regulation and future integration with intelligent health and rehabilitation-support devices. The NeuroVibe milestone also reflects growing development activity at the intersection of MedTech, artificial intelligence, digital health, neurotechnology and non-pharmacological intervention.
Datasea plans to continue product iteration, regulatory compliance activities, channel development and application validation as it seeks to establish a scalable acoustic AI platform. For cGxP and regulated medical technology stakeholders, the announcement is notable because it combines FDA device registration and listing, Class II medical device classification, AI-assisted analysis, EEG monitoring and non-invasive biofeedback technology. While NeuroVibe has not received FDA approval or 510(k) clearance, its device listing represents a step in Datasea’s planned U.S. commercialization pathway and development of its broader brain health technology portfolio.
Source: Datasea press release
